{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:07:51Z","timestamp":1749528471342,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,9]]},"DOI":"10.7759\/cureus.85652","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:41:48Z","timestamp":1749516108000},"source":"Crossref","is-referenced-by-count":0,"title":["Saroglitazar Versus Simvastatin for Metabolic and Alcohol-Associated Liver Disease (MetALD)"],"prefix":"10.7759","author":[{"given":"Anand","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid M","family":"Gangdany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramyashree","family":"Ramagundam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagaraja R","family":"Padaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231178370","article-title":"The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease","volume":"14","author":"Kulkarni AV","year":"2023","unstructured":"Kulkarni AV, Sarin SK. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease. Ther Adv Endocrinol Metab. 2023, 14:20420188231178370. 10.1177\/20420188231178370","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000935","article-title":"MetALD: does it require a different therapeutic option?","volume":"80","author":"Marek GW","year":"2024","unstructured":"Marek GW, Malhi H. MetALD: does it require a different therapeutic option?. Hepatology. 2024, 80:1424-40. 10.1097\/HEP.0000000000000935","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70012","article-title":"The lipidomic profile discriminates between MASLD and MetALD","volume":"61","author":"Schneider KM","year":"2025","unstructured":"Schneider KM, Cao F, Huang HY, et al.. The lipidomic profile discriminates between MASLD and MetALD. Aliment Pharmacol Ther. 2025, 61:1357-71. 10.1111\/apt.70012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117805","article-title":"Statins and non-alcoholic fatty liver disease: a concise review","volume":"183","author":"da Silva Pereira EN","year":"2025","unstructured":"da Silva Pereira EN, Franco RL, Santos RD, Daliry A. Statins and non-alcoholic fatty liver disease: a concise review. Biomed Pharmacother. 2025, 183:117805. 10.1016\/j.biopha.2024.117805","journal-title":"Biomed Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2\u00a0mg and 4\u00a0mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa M","year":"2020","unstructured":"Krishnappa M, Patil K, Parmar K, et al.. Effect of saroglitazar 2\u00a0mg and 4\u00a0mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol. 2020, 19:93. 10.1186\/s12933-020-01073-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117. 10.1038\/s41598-020-78342-x","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12610","article-title":"Peroxisome proliferator-activated receptors \u03b1 and \u03b3 are linked with alcohol consumption in mice and withdrawal and dependence in humans","volume":"39","author":"Blednov YA","year":"2015","unstructured":"Blednov YA, Benavidez JM, Black M, et al.. Peroxisome proliferator-activated receptors \u03b1 and \u03b3 are linked with alcohol consumption in mice and withdrawal and dependence in humans. Alcohol Clin Exp Res. 2015, 39:136-45. 10.1111\/acer.12610","journal-title":"Alcohol Clin Exp Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian National Association for Study of the Liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja A","year":"2023","unstructured":"Duseja A, Singh SP, De A, et al.. Indian National Association for Study of the Liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). J Clin Exp Hepatol. 2023, 13:273-302. 10.1016\/j.jceh.2022.11.014","journal-title":"J Clin Exp Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi R","year":"2022","unstructured":"Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al.. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022, 76:75-85. 10.1016\/j.jhep.2021.08.025","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.12.009","article-title":"The pattern of alcohol use in alcohol-related\u00a0cirrhosis in Indian patients: AUDIT Indian Liver Study","volume":"13","author":"Sharma M","year":"2023","unstructured":"Sharma M, Gora BA, Kulkarni A, et al.. The pattern of alcohol use in alcohol-related\u00a0cirrhosis in Indian patients: AUDIT Indian Liver Study. J Clin Exp Hepatol. 2023, 13:437-46. 10.1016\/j.jceh.2022.12.009","journal-title":"J Clin Exp Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/nu14030716","article-title":"Simvastatin improves microcirculatory function in nonalcoholic fatty liver disease and downregulates oxidative and ALE-RAGE stress","volume":"14","author":"Pereira EN","year":"2022","unstructured":"Pereira EN, Araujo BP, Rodrigues KL, et al.. Simvastatin improves microcirculatory function in nonalcoholic fatty liver disease and downregulates oxidative and ALE-RAGE stress. Nutrients. 2022, 14:716. 10.3390\/nu14030716","journal-title":"Nutrients"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47493","article-title":"Saroglitazar in non-alcoholic fatty liver disease from bench to bedside: a comprehensive review and sub-group meta-analysis","volume":"15","author":"Roy A","year":"2023","unstructured":"Roy A, Tewari B, Giri S, Goenka M. Saroglitazar in non-alcoholic fatty liver disease from bench to bedside: a comprehensive review and sub-group meta-analysis. Cureus. 2023, 15:e47493. 10.7759\/cureus.47493","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32094","article-title":"Letter to the editor: saroglitazar for treatment of NAFLD and NASH","volume":"74","author":"Kumar K","year":"2021","unstructured":"Kumar K, Kulkarni A, Jagdish RK. Letter to the editor: saroglitazar for treatment of NAFLD and NASH. Hepatology. 2021, 74:3559-60. 10.1002\/hep.32094","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000053","article-title":"Screening for alcohol use disorder and monitoring for alcohol use in the liver clinic","volume":"22","author":"Kulkarni AV","year":"2023","unstructured":"Kulkarni AV, Singal AK. Screening for alcohol use disorder and monitoring for alcohol use in the liver clinic. Clin Liver Dis (Hoboken). 2023, 22:219-24. 10.1097\/CLD.0000000000000053","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000664","article-title":"Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings","volume":"79","author":"Lee CM","year":"2024","unstructured":"Lee CM, Yoon EL, Kim M, Kang BK, Cho S, Nah EH, Jun DW. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024, 79:1393-400. 10.1097\/HEP.0000000000000664","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269531","article-title":"Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies","volume":"17","author":"Chhabra M","year":"2022","unstructured":"Chhabra M, Vidyasagar K, Gudi SK, Sharma J, Sharma R, Rashid M. Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies. PLoS ONE. 2022, 17:e0269531. 10.1371\/journal.pone.0269531","journal-title":"PLoS ONE"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359275-saroglitazar-versus-simvastatin-for-metabolic-and-alcohol-associated-liver-disease-metald","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:41:49Z","timestamp":1749516109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359275-saroglitazar-versus-simvastatin-for-metabolic-and-alcohol-associated-liver-disease-metald"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.85652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}